医学
脂肪变性
胰腺炎
胃肠病学
内科学
临床试验
多中心研究
急性胰腺炎
放射科
普通外科
随机对照试验
作者
Moon Jae Chung,Se Woo Park,Kyong Joo Lee,Da Hae Park,Dong Hee Koh,Jin Liu,Jun Young Lee,Jeong Youp Park,Seungmin Bang,Seonjeong Min,Ji Hoon Park,So Jeong Kim,Chan Hyuk Park
标识
DOI:10.1016/j.gie.2023.08.005
摘要
Pancreatic steatosis (PS) may be a risk factor for acute pancreatitis. Whether it is also a risk factor for post-ERCP pancreatitis (PEP) has not been evaluated. This study aimed to determine the impact of PS on PEP development.This multicenter prospective trial enrolled 786 consecutive patients who underwent contrast-enhanced abdominal CT and subsequent first-time ERCP. PS was evaluated based on pancreatic attenuation on unenhanced CT images. The risk of PS for the development of PEP was evaluated using a logistic regression model.Of 527 patients included in the study, 157 (29.8%) had PS and 370 (70.2%) did not. At 24 hours after ERCP, there was a significant difference in the PEP identified in 22 patients (14.0%) in the PS group and 23 patients (6.2%) in the "no PS" (NPS) group (P = .017). Diabetes and hypertension were more common in the PS group than in the NPS group; no differences in dyslipidemia were found. Patients with PS had a higher risk for the development of PEP than those with NPS (odds ratio, 2.09; 95% confidence interval, 1.08-4.03). No other variables were identified as risk factors for PEP.PS is a significant risk factor for PEP for which preventive measures should be considered. Standardized measurement protocols to assess PS by CT are needed. (Clinical trial registration number: KCT0006068.).
科研通智能强力驱动
Strongly Powered by AbleSci AI